Lung CancerNCT06424327
A Registry for People With Lung Cancer
An observational study of Lung Cancer and Lung Cancer Stage I, run by Memorial Sloan Kettering Cancer Center at 20 sites in 2 countries.
Trial summary
Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancer, Lung Cancer Stage I
- What is being tested?
- Patient-Reported Outcomes Measurement Information System
- How many people
- 600 participants
- Where
- 20 sitesin 2 countries
- Study dates
- 15 May 2024to 15 May 2029
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All study subjects will be recruited from their respective clinics (i.e., Thoracic Surgery, Pulmonary, Survivorship, etc.) at participating sites. Potential research subjects will be identified by a member of the patient's treatment team, the protocol investigator, or research team by screening patients' medical records. If eligible, the study will be discussed with each patient.
Who may be able to join
- Age ≥18 years
- Patients suitable for segmentectomy, according to the treating surgeon
- Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology
Who cannot join
- Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years
- History of chemotherapy or radiation therapy for a previous lung cancer
- Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery
- Carcinoid tumors
- History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
- Actively receiving treatment for other malignancies
- Cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis.
- Multi-segmental resection from the same lobe is not a criterion for exclusion.
Trial locations and contacts
20 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
20 sites in 2 countries
United States18 sites, 18 recruiting
- Recruiting
University of Michigan (Data Collection Only)
Ann Arbor, Michigan, 48109
Jules Lin, MD, 734-936-8857
- Recruiting
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920
David Jones, MD, 212-639-6428
- Recruiting
Massachusetts General Hospital Cancer Center (Data Collection Only)
Boston, Massachusetts, 02114
Michael Lanuti, MD, 617-726-6751
- Recruiting
Brigham and Women's Hospital (Data Collection Only)
Boston, Massachusetts, 02115
Paula A Ugalde Figueroa, MD, 617-525-7532
- Recruiting
Rush University Medical Center (Data collection only)
Chicago, Illinois, 606012
Christopher Seder, MD, 312-738-3732
- Recruiting
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack, New York, 11725
David Jones, MD, 212-639-6428
- Recruiting
Baylor University Medical Center (Data Collection Only)
Dallas, Texas, 75246
Shanda Blackmon, MD, MPH, 713-198-6376, sshanda.blackmon@bcm.edu
- Recruiting
Endeavor Health
Evanston, Illinois, 60201
Seth Krantz, MD, 847-570-2868
- Recruiting
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604
David Jones, MD, 212-639-6428
- Recruiting
MD Anderson Cancer Center (Data Collection Only)
Houston, Texas, 77030
David Rice, MD, 800-392-1611
- Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748
David Jones, MD, 212-639-6428
- Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645
David Jones, MD, 212-639-6428
- Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York, 10065
David Jones, MD, 212-639-6428
Yuan Liu, MD, PhD, 646-888-3640
- Recruiting
Thomas Jefferson University Hospital (Data Collection Only)
Philadelphia, Pennsylvania, 19107
Nathaniel Evans III, MD, nathaniel.evans@jefferson.edu
- Recruiting
ALLEGHENY HEALTH NETWORK (Data Collection Only)
Pittsburgh, Pennsylvania, 15212
Benny Weksler, MD, 412-359-6137
- Recruiting
University of California San Diego (Data collection)
San Diego, California, 92103
Joshua Boys, MD, 858-657-7777
- Recruiting
University of Arizona (Data Collection Only)
Tucson, Arizona, 85704
Praveen Sridhar, MD, 520-694-2873, psridhar@arizona.edu
- Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York, 11553
David Jones, MD, 212-639-6428
Canada2 sites, 2 recruiting
- Recruiting
Centre Hospitalier de l'Université de Montreal (Data Collection Only)
Montreal, Quebec, H2L 4M1
Moishe Liberman, MD. PhD, 514-890-8000, ext: 26832
- Recruiting
University Health Network (Data Collection Only)
Toronto, Ontario, M5G 2C4
Elliot Wakeam, MD, elliot.wakeam@uhn.ca
About this study
Official title: Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108
Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.
- Conditions
- Lung Cancer, Lung Cancer Stage I
- Being tested
- Patient-Reported Outcomes Measurement Information System
- Keywords
- lung cancer, lung cancer stage 1, segmentectomy, Memorial Sloan Kettering Cancer Center, 24-127
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Patient-Reported Outcomes Measurement Information SystemOther
Also called PROMIS
Participants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0)
| Study group | Role | What they receive |
|---|---|---|
| Participants with Lung Cancer | Participants undergoing planned pulmonary segmentectomy for primary lung cancer Receives: Other: Patient-Reported Outcomes Measurement Information System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.
DFS is measured from the date of surgery to the date of recurrence or death
Measured: 3 years
Determine 5-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.
DFS is measured from the date of surgery to the date of recurrence or death
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2024
- Study start15 May 2024
- Primary completion15 May 2029 (estimated)
- Study completion15 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- David Jones, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06424327
- Sponsor's protocol ID
- 24-127
- Status last verified
- Sep 2026
- First submitted
- 16 May 2024
- Last updated
- 24 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pulmonary Segmentectomy for Lung Cancer: A Real-World International Registry-TSOG 108
- ClinicalTrials.gov ID
- NCT06424327
- Acronym / sponsor ID
- 24-127
- Conditions
- Lung Cancer, Lung Cancer Stage I
- Keywords
- lung cancer, lung cancer stage 1, segmentectomy, Memorial Sloan Kettering Cancer Center, 24-127
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Study start
- 15 May 2024 (actual)
- Primary completion
- 15 May 2029 (estimated)
- Study completion
- 15 May 2029 (estimated)
- First posted
- 22 May 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants with Lung Cancer | – | Other: Patient-Reported Outcomes Measurement Information SystemParticipants undergoing planned pulmonary segmentectomy for primary lung cancer |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All study subjects will be recruited from their respective clinics (i.e., Thoracic Surgery, Pulmonary, Survivorship, etc.) at participating sites. Potential research subjects will be identified by a member of the patient's treatment team, the protocol investigator, or research team by screening patients' medical records. If eligible, the study will be discussed with each patient.
Key inclusion criteria (3 listed)
- Age ≥18 years
- Patients suitable for segmentectomy, according to the treating surgeon
- Clinical Stage I with suspected NSCLC, classified preoperatively based on the AJCC TNM staging manual, 9th edition o Note: Tissue diagnosis of NSCLC is not required before enrollment. A pathologic diagnosis of NSCLC may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology
Key exclusion criteria (8 listed)
- Actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years
- History of chemotherapy or radiation therapy for a previous lung cancer
- Synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery
- Carcinoid tumors
- History of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Patient-Reported Outcomes Measurement Information SystemAlso: PROMISParticipants-reported outcomes will be collected using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS is a web-based platform developed by the National Institutes of Health. Scoring is standardized on a scale from 0 to 100, with a population mean of 50 and standard deviation of 10 units. High scores mean more of the concept being measured. This study will use PROMIS surveys assessing three domains: physical function (PROMIS bank version 2.0), pain interference (PROMIS bank version 1.1), and dyspnea severity (PROMIS bank version 1.0) | Other | Participants with Lung Cancer |
Primary outcome
Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.
Time frame: 3 years
DFS is measured from the date of surgery to the date of recurrence or death
Determine 5-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer.
Time frame: 5 years
DFS is measured from the date of surgery to the date of recurrence or death
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
David Jones, MD principal investigator
Memorial Sloan Kettering Cancer Center
20 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer and Lung Cancer Stage I, run by Memorial Sloan Kettering Cancer Center at 20 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact David Jones, MD (212-639-6428, jonesd2@mskcc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Determine 3-year disease-free survival/DFS among patients undergoing pulmonary segmentectomy for lung cancer. (time frame: 3 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.